Cannabis Science, Inc. : Cannabis Science Reports Second Cancer Patient Receives Clean Biopsy Report Confirming the Biopsy is Free of Cancer Cells
04/04/2012| 01:15pm US/Eastern
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company
developing pharmaceutical cannabis (marijuana) products is happy to
report that patient #2, who had a Squamous cell carcinoma on her arm,
has received her biopsy report. It confirms what was visually apparent
from the photo-documentation on our website. Her biopsy was free of
cancer cells and she will not need any surgical procedure. Nevertheless,
the patient will continue with her self-administered topical application
of extracts for a while longer to minimize any chance of any surviving
cancer cells in areas beyond what was biopsied.
Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D.,
stated, "Squamous cell carcinomas have a much greater invasive potential
than is typical of basal cell carcinomas. Photo-documentation of topical
cannabis extract treatments of patient #2 and patient #3 dramatically
demonstrate how the treatment appear to extrude the subcutaneous tumor
to the surface as the killing and subsequent healing proceeds. Patient
#3 reports continued progress as his tumors appear to shrink and the
pain levels continue to improve. The patient's wife commented that about
75% of the large tumor mass is gone. We will continue with 'live
updates' as new pictures and physician reports are made available to us."
You can view the patient's photographs during the treatment process, as
well as the full biopsy report from the physician, on the Cannabis
Science website www.cannabisscience.com.
Click the button "View Images of 2nd Self-Medicated Patient &
The Apparent Success" to view the full biopsy report, photos and
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade
medical marijuana research and development. The second formulations will
address the needs of patients choosing to use concentrated cannabis
extracts to treat their ailments. Eventually, all Americans will have
access to a safe and effective FDA approved medicine regardless of which
state they live in. To maintain that marijuana is a dangerous, addictive
drug with no medical value is scientifically absurd. Cannabis medicines,
with no effective lethal dose, are far safer than aspirin,
acetaminophen, and most other OTC drugs that kill thousands of Americans
every year. The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize
phytocannabinoid-based pharmaceutical products. In sum, we are dedicated
to the creation of cannabis-based medicines, both with and without
psychoactive properties, to treat disease and the symptoms of disease,
as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Act of 1934. A statement containing works such as
"anticipate," "seek," intend," "believe," "plan," "estimate," "expect,"
"project," "plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results anticipated by
these forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and global
economies, the impact of competition, and the Company's reliance on
existing regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does it
intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
VP Investor Relations
© Business Wire 2012